FMP

FMP

Enter

VTVT - vTv Therapeutics Inc...

Financial Summary of vTv Therapeutics Inc.(VTVT), vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of ora

photo-url-https://financialmodelingprep.com/image-stock/VTVT.png

vTv Therapeutics Inc.

VTVT

NASDAQ

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

27.72 USD

-1.18 (-4.26%)

About

ceo

Mr. Paul J. Sekhri M.Sc.

sector

Healthcare

industry

Biotechnology

website

https://www.vtvtherapeutics.com

exchange

NASDAQ

Description

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approac...

CIK

0001641489

ISIN

US9183852048

CUSIP

918385105

Address

3980 Premier Drive

Phone

336 841 0300

Country

US

Employee

16

IPO Date

Jul 30, 2015

Summary

CIK

0001641489

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

918385105

ISIN

US9183852048

Country

US

Price

27.72

Beta

0.52

Volume Avg.

66.24k

Market Cap

67.44M

Shares

-

52-Week

7.38-39.6

DCF

4.28

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.85

P/B

-

Website

https://www.vtvtherapeutics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest VTVT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep